Literature DB >> 12500201

Clinical profile of autosomal dominant polycystic liver disease.

Qi Qian1, Airong Li, Bernard F King, Patrick S Kamath, Donna J Lager, John Huston, Clarence Shub, Sonia Davila, Stefan Somlo, Vicente E Torres.   

Abstract

Most reports on the natural history, manifestations, and treatment of polycystic liver disease are based on the disease as it manifests in patients with autosomal dominant polycystic kidney disease (ADPKD). The purpose of this study was to develop a clinical profile of isolated autosomal dominant polycystic liver disease (ADPLD) using nonaffected family members as controls. The study included 146 probands, known affected relatives, and first-degree relatives of affected individuals. Participants underwent a formalized medical history interview and physical examination, ultrasonographic examination of the liver and kidneys, magnetic resonance angiography of the brain, and echocardiography. Thirty-eight of the 49 individuals diagnosed with polycystic liver disease before participation in the study were or had been symptomatic. Of 97 previously undiagnosed at-risk individuals, 23 were affected, 39 were unaffected, and 35 were indeterminate. Compared with patients with a negative or indeterminate diagnosis, those with polycystic liver disease had slightly higher levels of serum alkaline phosphatase and total bilirubin and lower levels of total cholesterol and triglycerides. Female patients had a significantly higher mean cyst score than male patients. The cysts were found to arise from the dilatation of biliary microhamartomas and from peribiliary glands. Structural mitral leaflet abnormalities were detected more frequently in affected than in indeterminate or nonaffected individuals. A vascular phenotype was detected in 5.6% of the patients with isolated ADPLD diagnosed clinically and/or by linkage analysis but in none of the unaffected patients. In conclusion, isolated ADPLD is underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with similar pathogenesis, manifestations, and management.

Entities:  

Mesh:

Year:  2003        PMID: 12500201     DOI: 10.1053/jhep.2003.50006

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  52 in total

1.  Hepatorenal findings in obligate heterozygotes for autosomal recessive polycystic kidney disease.

Authors:  Meral Gunay-Aygun; Baris I Turkbey; Joy Bryant; Kailash T Daryanani; Maya Tuchman Gerstein; Katie Piwnica-Worms; Peter Choyke; Theo Heller; William A Gahl
Journal:  Mol Genet Metab       Date:  2011-09-08       Impact factor: 4.797

2.  Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.

Authors:  Ramón Peces; Joost P H Drenth; Rene H M Te Morsche; Pedro González; Carlos Peces
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 3.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

4.  Sec63 and Xbp1 regulate IRE1α activity and polycystic disease severity.

Authors:  Sorin V Fedeles; Jae-Seon So; Amol Shrikhande; Seung Hun Lee; Anna-Rachel Gallagher; Christina E Barkauskas; Stefan Somlo; Ann-Hwee Lee
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

5.  Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease.

Authors:  Julie Benzimra; Maxime Ronot; David Fuks; Mohamed Abdel-Rehim; Annie Sibert; Olivier Farges; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2014-02-22       Impact factor: 5.315

Review 6.  Evaluation of hepatic cystic lesions.

Authors:  Marten A Lantinga; Tom J G Gevers; Joost P H Drenth
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

7.  Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.

Authors:  Matthew B Lanktree; Amirreza Haghighi; Elsa Guiard; Ioan-Andrei Iliuta; Xuewen Song; Peter C Harris; Andrew D Paterson; York Pei
Journal:  J Am Soc Nephrol       Date:  2018-08-22       Impact factor: 10.121

Review 8.  Surgical management of polycystic liver disease.

Authors:  Robert T Russell; C Wright Pinson
Journal:  World J Gastroenterol       Date:  2007-10-14       Impact factor: 5.742

9.  Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Paolo Onori; Romina Mancinelli; Antonio Franchitto; Guido Carpino; Anastasia Renzi; Stefania Brozzetti; Julie Venter; Heather Francis; Shannon Glaser; Douglas M Jefferson; Gianfranco Alpini; Eugenio Gaudio
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

10.  Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%.

Authors:  Loes van Keimpema; Jelle P Ruurda; Miranda F Ernst; Hendrikus J A A van Geffen; Joost P H Drenth
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.